Business Wire

Airlines Were on Time in 2020, but Passenger Flights Operated Halved Compared to 2019, Reveals Cirium

4.1.2021 20:15:00 EET | Business Wire | Press release

Share

Over 180 of the major global airlines were on time in 2020, according to a new report by Cirium, the global aviation data company. The Cirium Airline Insights Review 2020 reveals that only 30 major airlines achieved this standard pre-pandemic. But over 60%—or 180 of 300 airlines globally—achieved a 90% or higher on-time arrival percentage since February 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210104005632/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cirium’s new report The Cirium Airline Insights Review 2020 reveals the world’s top 10 busiest airports of 2020. (Graphic: Business Wire)

On-time performance of the top 300 global airlines significantly improved as COVID-19 reduced the number of flights in the air. In 2020, airlines only flew half of the flights flown the previous year.

“The pandemic caused a significant reduction in flight volume with airlines operating 49% fewer flights in 2020. The factors that normally cause flight delays didn’t exist, such as congestion at the airport. Overall global passenger traffic was down in 2020 by 67% from the previous year,” said Jeremy Bowen, CEO of Cirium.

Cirium’s top 10 league table for flights operated by country shows that the majority of flights were operated in the US, despite a 42% year-over-year drop in the market. China maintained its position, with only 24% of that market’s flights down versus 2019.

Japan overtook India, moving up to 3rd place as India’s flights were down 50% versus 2019. The UK was hit heavily with 67% of flights down compared to last year, moving it to 8th place from 5th. Russia moved from 10th place in 2019 to 5th in 2020 and Indonesia moved into the top 10.

Top 10 countries by passenger flights flown 2020

Rank

Country

Total flights flown 2020

Rank in 2019

% YoY diff

1

United States

5.1M

#1

-42%

2

China

3.4M

#2

-24%

3

Japan

638K

#4

-43%

4

India

592K

#3

-50%

5

Russia

486K

#10

-34%

6

Brazil

382K

#9

-53%

7

Spain

352K

#7

-61%

8

United Kingdom

340K

#5

-67%

9

Indonesia

333K

#12

-53%

10

Mexico

332K

#15

-44%

 

Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021

Asia-Pacific carriers recovered much quicker in 2020 than their global peers and rose in the rankings in flights operated. Out of the top 10 global airlines, China Southern Airlines’ passenger flights only dropped 28% versus 2019. United Airlines was the most impacted of the top 10, with a 54% drop in flights flown versus 2019.

No European carriers feature in the 2020 list. Ryanair moved to 13th place (from 6th) as the airline’s flights flown were down 72% versus the year before. Lufthansa was 11th in 2019 but missed out on the 2020 top 10, finishing at 29th place as flights flown dropped by 69% in 2020.

Top 10 airlines by passenger flights flown 2020

Rank

Airline code

Airline

Total flights flown 2020

Rank in 2019

% YoY diff

1

WN

Southwest Airlines

896K

#1

-34%

2

AA

American Airlines

622K

#3

-44%

3

DL

Delta Air Lines

619K

#2

-46%

4

OO

SkyWest Airlines

597K

#4

-30%

5

CZ

China Southern Airlines

521K

#7

-28%

6

UA

United Airlines

372K

#5

-54%

7

MU

China Eastern Airlines

321K

#9

-33%

8

CA

Air China

312K

#10

-30%

9

6E

IndiGo

281K

#8

-45%

10

YX

Republic Airways

217K

#15

-37%

Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021

“Domestic travel has recovered faster and airlines with a dominant domestic market come back quicker,” Bowen said. “That is especially the case in Asia-Pacific where recovery is more positive. The US and Europe have experienced setbacks with government-enforced restrictions and additional waves of COVID-19 affecting travel.”

Travel restrictions and the shift to more leisure travel versus business travel changed the top 10 league table for flights flown by airport extensively.

Chicago O’Hare is usually the busiest airport globally for passenger flights, however the pandemic caused a 46% reduction in flights for the airport in 2020. Three Chinese airports—Guangzhou Baiyun, Chengdu Shuangliu, and Shenzhen Bao’an—moved into the global top 10 busiest airports by arriving passenger flights.

Top 10 airports by passenger flights flown 2020

Rank

Airport code

Airport

Total flights flown 2020

Rank in 2019

% YoY diff

1

ATL

Atlanta US

260K

#2

-40%

2

DFW

Dallas US

235K

#3

-30%

3

ORD

Chicago US

234K

#1

-46%

4

DEN

Denver US

202K

#5

-32%

5

CLT

Charlotte US

182K

#7

-32%

6

CAN

Guangzhou CN

165K

#13

-28%

7

LAX

Los Angeles US

156K

#4

-50%

8

CTU

Chengdu CN

148K

#37

-16%

9

SZX

Shenzhen CN

139K

#42

-16%

10

SEA

Seattle US

137K

#18

-36%

Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021

In 2019, London Heathrow was the 9th busiest airport for flights flown. In 2020, it ranked 31st and flights operating there were down 61% versus 2019. Amsterdam Airport Schiphol was the busiest airport in Europe. Flight operations there dropped 57% in 2020 and as a result the airport sits at 27th globally.

The Cirium Airline Insights Review 2020 provides additional insights on 2020 air travel industry and includes The On-Time Performance Review 2020 by Cirium.

To read the full Cirium Airline Insights Review 2020 – click here.

Ends

Note to editors:

Data for the passenger flights flown is based on set criteria, which includes passenger flights only (including combination flights – passenger and cargo) that are scheduled and aircraft market classes of narrowbody, widebody, and regional jets. It excludes other types, such as cargo and business jet flights, as well as unscheduled flights.

For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter.

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries, please contact,

In the UK: Paul Charles / Michael Johnson / Balint Brunner at The PC Agency via cirium@pc.agency or +44 207 768 0001

In the Americas: Mike Arnot, at Juliett Alpha via cirium@juliettalpha.com

In Asia-Pacific: Tracy Cheung, at Cirium via tracy.cheung@cirium.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye